3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
26
Phase 1
7
Phase 1/2
6
Phase 3
3
Phase NA
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Conditions
Neuroendocrine Tumors
3
Interventions
Cisplatin
294
Radiotherapy
230
Fluorouracil
201
Cyclophosphamide
191
Capecitabine
183
Docetaxel
167
Gemcitabine
165
Oxaliplatin
162
Carboplatin
161
Paclitaxel
152
Leucovorin
122
Drug Therapy
119
Dexamethasone
119
Doxorubicin
112
Etoposide
99
Bevacizumab
91
Cytarabine
87
Vincristine
83
Irinotecan
81
Rituximab
77
Epirubicin
71
Prednisone
65
Radiosurgery
63
Methotrexate
62
Surgical Procedures, Operative
61
Radiation
60
Radiotherapy, Intensity-Modulated
57
Neoadjuvant Therapy
53
Lenalidomide
52
Letrozole
51
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
OTHER
×
lutetium Lu 177 dotatate
×
Clear all
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled
NCT01842165
2022-11-10
LUMEN
Jules Bordet Institute
Phase 3
Completed
37 enrolled
NCT01860742
2016-04-05
CASTOR
Jules Bordet Institute
Phase 3
Withdrawn